Slide 1: Investor Presentation Q4 2016
Investor Presentation Q4 2016 (OTCQB: IMMD) www.immudyne.com
Slide 2: Safe Harbor
Statements in this presentation that are not descriptions of historical facts are forward - looking statements relating to future events, and as such all forward - looking statements are made pursuant to the Securities Litigation Reform Act of 1995 . Statements may contain certain forward - looking
Slide 3: Overview
Overview ▪ ImmuDyne is a leader in the development and marketing of OTC heath and wellness products addressing large and unmet needs ▪ The company is focused on marketing its safe and efficacious products based on its proprietary immune - modulator, Beta - 1/3,1/6 - glucan ▪ Clinically shown to prot
Slide 4: Corporate Highlights
Corporate Highlights ▪ 391 % increase in revenue through Q3 2016 ▪ Profitable ▪ Strong cash position and conservative monthly overhead ▪ Large unmet need; $18B U.S. skincare market lacks products that ‘work’ ▪ Fast path to commercialization with new SKUs addressing cumulative $50+ billion opportunit
Slide 5: What is Beta-1/3,1/6-glucan?
What is Beta - 1/3,1/6 - glucan? ▪ Beta - 1/3,1/6 - glucan (“ β - glucan ”) is a safe and potent immune modulator derived from the cell wall of Baker’s yeast ▪ Natural polysaccharide that b inds to the dectin - 1, CR3, and TLR receptors found on immune cells, including natural killer (NK) cells, den
Slide 6: Clinically Proven In Skin Applications
β - glucan Clinically Proven In Skin Applications ▪ 150 - patient study demonstrated statistically - significant (p - value =<0.0005) improvement in skin health (Leung et al.) after 28 and 56 days, respectively ▪ ImmuDyne’s β - glucan was formulated for skincare application topically and applied twi
Slide 7: vs. Competition in $18B Skin Market
β - glucan vs. Competition in $18B Skin Market ▪ Popular anti - aging creams rely on synthetic peptides to stimulate skin cells to produce collagen; the clinical benefit is usually not proven. ▪ Botulinum toxin, or Botox ($2.2B, FY’14 sales) injection made by Allergan enhances the appearance of skin
Slide 8: Product Portfolio
Product Portfolio ImmuDyne is developing β - glucan as a natural alternative or adjuvant agent for serious, unmet medical needs in oncology, infectious disease and wound care. Our SGM delivery technology offers the potential for rapid onset action, extended - release and more potent drug activity. N
Slide 9: ImmuDyne subsidiary Inate Scientific
ImmuDyne subsidiary Inate Scientific ▪ 39,648 trial orders as of 9/30/16 ▪ Anticipate launch of straight sale product line in Q4 of 2016 with improved margins and better customer retention ▪ 3 new products recently added to this SKU We believe that our clinically activity β - glucan products, if mar
Slide 10: Key Scientific Publications
Key Scientific Publications Of β - glucan ▪ Immune - Regulating Properties. Immune - modulatory effects of dietary Yeast Beta - 1,3/1,6 - D - glucan (Nutritional Journal, Stier et al) ▪ Adjuvant For Cancer Therapy. Therapeutic potential of various beta - glucan sources in conjunction with anti - tum
Slide 11: Strong Management & BOD
Strong Management & BOD ▪ Mark McLaughlin , President & CEO, former SVP at Oppenheimer & Co., Lehman Brothers. Led ImmuDyne's commercial build - out, and turn - around to profitable biotech company. ▪ Dr. Anthony Bruzzese , Chairman, Radiologist certified by the American Board of Internal Medicine a
Slide 12: Upcoming Catalysts
Upcoming Catalysts IMMD will see multiple value - creating milestones: ▪ Profitability expected in Fiscal 2016 ▪ Results of BIO - EC study expected to open new market in Q4 (topical application, anticipate new patent to be filed in late October, 2016 and seek path to commercialization with strategic
Slide 13: Investment Summary
Investment Summary ▪ Profitable & Growing. Immudyne is profitable and is anticipating triple digit sales growth in FY2016. ▪ Proprietary & Effective Product. We manufacture, sell and out - license the purest, all natural yeast beta glucan on the market. β - glucan has been proven in thousands of cli
Slide 14: Investor Contact
www.immudyne.com OTCQB: IMMD Investor Contact: Mark McLaughlin, CEO markmcl@immudyne.com 14